Data from European Society for Medical Oncology (ESMO) - Curated by EPG Health - Last updated 10 April 2018

Status

live

Latest update

25-Aug-15

Dyspnoea is described as difficult or laboured breathing and is a frequent symptom in advanced cancer patients, with the highest prevalence in lung cancer. Dyspnoea has been demonstrated to be one of the most distressing cancer symptoms and requires a multidisciplinary approach in patient management and care. The new ESMO Clinical Practice Guidelines on the treatment of dyspnoea in advanced cancer patients focus on dyspnoea management strategies including treating reversible causes, non-pharmacological interventions and pharmacological treatment such as opioids, benzodiazepines and other drugs.

Read full guideline

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars Knowledge Centre

Biosimilars Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

Related Content